Clinical Study | Office of Clinical Research

Phase III Trial Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of Her2-Overexpressing Esophageal Adenocarcinoma

Posted Date: May 15, 2019

Investigator: Jordan Kharofa
Type of Study: Drug

Standard treatment for esophageal adenocarcinoma is treatment with radiation therapy and the chemotherapy drugs paclitaxel and carboplatin. Afterwards, surgery is done to remove the esophagus. This study will test whether the addition of the drug tastuzumab to standard treatment can help prevent you

Criteria:

Eligible Patients Must Have Cancer Of The Esophagus

Keywords:

Esophageal Cancer, Esophagus, Gastrointestinal Can, Gi Cancer, R1010

For More Information:

Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List